NEWS: 公告在東京證券交易所JASDAQ標準市場新上市


注射器市場 - 成長,趨勢,預測(2019年∼2024年)

Syringe Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 851141
出版日期 內容資訊 英文 130 Pages
商品交期: 2-3個工作天內
注射器市場 - 成長,趨勢,預測(2019年∼2024年) Syringe Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年04月21日內容資訊: 英文 130 Pages



第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各使用
    • 殺菌、可重複使用類型
    • 拋棄式類型
    • 預填充式注射器
  • 各用途
    • 胰島素注射
    • 肉毒桿菌
    • 骨關節炎
    • 人體生長荷爾蒙
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東&非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Becton Dickinson and Company.
    • B. Braun Melsungen AG.
    • Gerresheimer AG.
    • Hindustan Syringes & Medical Devices Limited
    • Terumo Corporation.
    • Nipro Corporation.
    • Schott AG.
    • Cardinal Health.
    • Smiths Medical.
    • Codan Medizinische Gerte GmbH & Co. KG.
    • Catalent Inc.

第7章 市場機會及未來趨勢


Product Code: 58869

The Syringe market is projected to witness a CAGR of around 10.1% during the forecast period, with a revenue of approximately USD 13,852 million in 2020 and expected to reach USD 24,920 million by 2026.

Due to COVID-19, the rise in the development of COVID-19 Vaccines has been observed, which will lead to increased demand for syringes. In January 2020, Biomedical Advanced Research and Development Authority (BARDA) estimated that between 650 million to 850 million needles and syringes would be needed to administer a vaccine in the U.S. alone. As a result, the demand for syringes is expected to increase, which may boost the market growth.

The major factors driving the growth of the Syringe market include the growing prevalence of chronic and infectious diseases and the increase in the usage of Botox for therapeutic applications. As per the International Diabetes Federation 2019 report, the number of people living with diabetes is expected to increase from 463 million in 2019 to nearly 700 million by 2045. Most of the diagnostic and therapeutic techniques for chronic diseases require syringes, as these play a vital role during tests and drug administration, which will lead to its increased demand.

Moreover, the increased adoption of injectable drugs, technological advancements in syringes, the increase in the geriatric population, growing number of vaccination and immunization programs are also expected to drive the volume growth over the next few years. According to World Population Prospects 2019 report (United Nations, 2019), there were about 703 million people aged 65 years or over in the world in 2019. The number of elderly population is projected to double to 1.5 billion in 2050. Worldwide, the share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019. Moreover, by 2050, approximately 1 in 6 people,globally will be over the age of 65. As the elderly population is expected to grow worldwide and chronic disease being the high-risk factor in this population will drive the market in near future.

On the other hand, the rise in the incidence of needle-stick injuries, a high cost associated with safety syringes, and availability of alternate drug delivery methods are likely to hinder the growth of the syringe market globally.

Key Market Trends

Prefilled Syringes are Expected to Contribute at Good Rate Over the Forecast Period

Prefilled syringes are gaining acceptance in the market as drug delivery systems designed for injectable drugs. Prefilled syringes provide the advantage of precise dosing as the syringes are already loaded with a dose worth of the drug. These are generally preferred for parenteral administration of various drugs and are used mainly for the treatment of chronic diseases, such as Cancer, Diabetes and several other disease.

The COVID-19 outbreak is also leading to increased demand for prefilled syringes. In November 2020, ApiJect announced the approval of a USD 590 million loan from the U.S. International Development Finance Corporation to support building a United States-based facility with surge capacity to produce up to 3 billion single-dose prefilled plastic injectors per year, with no supply chain limitations. ApiJect's new campus will have 15 production lines to fill and finish vaccines and therapeutics for COVID-19.

Furthermore, many pharmaceutical companies are focusing on bringing in advancements in self-administration therapies. The shift from glass prefilled syringes to plastic pre-filled syringes has been observed among healthcare professionald and patient population. The plastic prefilled syringes are becoming more popular due to the introduction of advanced polymer materials, such as polypropylene and crystal-clear polymer, which are biocompatible with the other components of the syringe.

Hence, owing to the aforementioned factors, along with rising geriatric population, the studied market is expected to witness rapid growth.

Asia-Pacific is Expected to Grow at Healthy Rate Over the Forecast Period

The Asia-Pacific market for syringes is expected to witness healthy growth during the forecast period. Factors, such as improving economic conditions, rise in purchasing power of the people, the growth in awareness regarding the advantages of prefilled syringes, and the presence of a large patient pool suffering from various chronic diseases are expected to drive the market in Asia-pacific region.

The market players are continuously focusing on product launches, which is driving the market growth in the region. For instance, in August 2019, Sunshine Guojian Pharmaceutical, a subsidiary of 3SBio have announced the approval of Yisaipu, a biosimilar of Enbrel (etanercept), as a pre-filled syringe to treat ankylosing spondylitis in China.

Moreover, due to the coronavirus outbreak, there is higher demand for syringes in the region. The COVID-19 pandemic has resulted in a large number of individuals admitted to hospitals. These hospital admissions are followed by various tests using blood samples and injection of various medications to subdue the symptoms due to the virus, which is expected to further fuel the market growth.

Competitive Landscape

The syringe market is highly fragmented with the presence of a large number of local and international players. Key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. For instance, in 2019 - Fresenius Kabi launched Adenosine Injection, USP in 6 mg per 2 mL and 12 mg per 4 mL single dose in Simplist ready-to-administer prefilled syringes in the United States.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic Diseases and Infectious Diseases
    • 4.2.2 Increased Adoption of the Injectable Drugs
    • 4.2.3 Technological Advancements in Syringes by Medical Device Companies
  • 4.3 Market Restraints
    • 4.3.1 Growing Cases of Needle-stick Injuries, Coupled with High Cost of Safety Syringes
    • 4.3.2 Availability of Alternate Drug Delivery Methods
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Usage
    • 5.1.1 Sterilizable/Reusable Syringes
    • 5.1.2 Disposable Syringes
      • Conventional Syringes
      • Safety Syringes
      • Prefilled Syringes
  • 5.2 By Application
    • 5.2.1 Insulin Syringes
    • 5.2.2 Botox
    • 5.2.3 Osteoarthritis
    • 5.2.4 Human Growth Hormone
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States (By Usage and By Application)
      • Canada (By Usage and By Application)
      • Mexico (By Usage and By Application)
    • 5.3.2 Europe
      • Germany (By Usage and By Application)
      • United Kingdom (By Usage and By Application)
      • France (By Usage and By Application)
      • Italy (By Usage and By Application)
      • Spain (By Usage and By Application)
      • Rest of Europe (By Usage and By Application)
    • 5.3.3 Asia-Pacific
      • China (By Usage and By Application)
      • Japan (By Usage and By Application)
      • India (By Usage and By Application)
      • Australia (By Usage and By Application)
      • South Korea (By Usage and By Application)
      • Rest of Asia-Pacific (By Usage and By Application)
    • 5.3.4 Middle East and Africa
      • GCC (By Usage and By Application)
      • South Africa (By Usage and By Application)
      • Rest of Middle East and Africa (By Usage and By Application)
    • 5.3.5 South America
      • Brazil (By Usage and By Application)
      • Argentina (By Usage and By Application)
      • Rest of South America (By Usage and By Application)


  • 6.1 Company Profiles
    • 6.1.1 Becton Dickinson and Company.
    • 6.1.2 B. Braun Melsungen AG
    • 6.1.3 Gerresheimer AG
    • 6.1.4 Hindustan Syringes & Medical Devices Limited
    • 6.1.5 Terumo Corporation
    • 6.1.6 Nipro Corporation
    • 6.1.7 Schott AG
    • 6.1.8 Cardinal Health Inc.
    • 6.1.9 Smiths Medical
    • 6.1.10 Henry Schein, Inc.
    • 6.1.11 Johnson & Johnson
    • 6.1.12 Baxter International Inc.
    • 6.1.13 Pfizer Inc.
    • 6.1.14 Teva Pharmaceuticals Industries Ltd
    • 6.1.15 Fresenius SE & Co. KGaA